Addiction (Abingdon, England)
July 7, 2026
Johanna J Nugteren-Van Lonkhuyzen, Irma S Van den Hengel-Koot, Claudine C Hunault et al.
Data on the presence of new psychoactive substances (NPS) mainly originate from drug-checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands. We investigated temporal trends in NPS poisonings reported to the Dutch Poisons Information Center (DPIC) between 2012 and...
Addiction (Abingdon, England)
July 1, 2026
Daniel T. Myran, Rachael MacDonald-Spracklin, Alexander R Levesque et al.
Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics of individuals with ED visits involving hallucinogens. Repeated...
Addiction (Abingdon, England)
March 30, 2026
Sarah J Catchlove, Katrin Oliver, Michael Savic et al.
Australia recently down-scheduled and authorised psychedelic-assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness. While service leaders and clinicians are crucial to implementation, little research examines their...
Addiction (Abingdon, England)
January 29, 2026
Yi-Hsuan Liu, Chia-Chun Hung, Marc N Potenza et al.
Recreational ketamine use has increased globally and is associated with psychiatric and cognitive concerns. The hippocampus in preclinical models shows damage and working-memory disruption with repeated dosing. However, whether specific hippocampal subregions may differ in people with chronic ketamine use remains unclear. In Taiwan, ketamine is predominantly consumed by smoking ketamine mixed...
Addiction (Abingdon, England)
January 20, 2026
Tibor Markus Brunt
2 citations
Revived interest in psychedelic-assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti-addictive potential. Evidence from observational, open-label, and limited randomized placebo-controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in opioid and cocaine-dependent individuals, primarily...
Addiction (Abingdon, England)
December 1, 2025
Zachary Bryant, Kirsten Morley, Jessica A Kerr et al.
MDMA (3,4-methylenedioxymethamphetamine or "Ecstasy") is the fourth-most used illicit substance globally. While previous research found links between MDMA use and mental health outcomes, the direction and nature of this relationship remain unclear. This study assessed whether MDMA use in early adulthood increases the risk of anxiety or depression in mid-30s. A longitudinal, population-based...
Addiction (Abingdon, England)
July 23, 2025
Tran Thi Thanh Hue, Hieu K T Ngo, Zhe Wang et al.
2 citations
Illicit drug use causes great harm and economical loss to society, yet there is limited understanding of its prevalence in the population in low-income countries like Vietnam where survey resources are scarce. In this study, we used wastewater analysis as a cost-effective monitoring tool to measure illicit drug use in a population of Hanoi, Vietnam, a low-income country in Southeast Asia. This...
Addiction (Abingdon, England)
April 28, 2025
Rebecca Harding, Tamsin Barton, Maeve Niepceron et al.
14 citations
To report the symptoms and aetiology of ketamine use disorder (KUD), gauge the effectiveness of current treatment services and identify strategies to enhance patient access and outcomes. Mixed-methods, cross-sectional questionnaire. Electronic survey from November 2023 to April 2024. Participants were recruited through snowball sampling, social media and referrals from UK addiction treatment...
Addiction (Abingdon, England)
April 20, 2025
Joseph J Palamar, Nina Abukahok, Patricia Acosta et al.
7 citations
'Tusi', also known as 'tusibí' or 'pink cocaine', is a drug concoction which previously emerged in Latin America and Europe and has recently acquired popularity in the United States (US). Consumers are often unaware that Tusi contains a mixture of ketamine and other drugs, and the concoction can be confused with 2C/2C-B (ring-substituted phenethylamines/4-bromo-2,5-dimethoxyphenethylamine) or...
Addiction (Abingdon, England)
April 4, 2025
Asem Abdelrahman, Mo Belal
4 citations
Ketamine-induced cystitis is an increasingly recognized complication associated with the addictive use of ketamine, a dissociative anesthetic. This article provides a comprehensive overview, focusing on its pathophysiology, clinical presentation, diagnosis, management strategies, and implications for addiction treatment. The British Association of Urological Surgeons consensus serves as a...
Addiction (Abingdon, England)
January 16, 2025
Noa Krawczyk, Megan Miller, Emma Yuanqi Gu et al.
2 citations
The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing needs. Psychedelics are emerging as a possible alternative therapy for mental health and substance use disorders. This study aimed to gather insights on how people use or are considering using psychedelics to manage opioid use disorder (OUD), how these...
Addiction (Abingdon, England)
2025
Leigh Coney, Amy Peacock, Daan van der Gouwe et al.
8 citations
Drugs sold on cryptomarkets are thought to have lower levels of adulteration and higher strength compared with those sourced off-line. The present study aimed to determine whether cryptomarket and off-line-sourced 3,4-methylenedioxy-N-methamphetamine (MDMA), cocaine, amphetamine, methamphetamine and lysergic acid diethylamide (LSD) differed in adulteration and strength. A between-groups design...
Addiction (Abingdon, England)
June 1, 2023
Cassidy R Loparco, Matthew E Rossheim, Scott T Walters et al.
Delta-8 tetrahydrocannabinol (THC) is a psychoactive substance from the Cannabis plant that has been rising in popularity in the United States since the 2018 US Farm Bill implicitly legalized it. This study reviewed research from peer-reviewed and non-peer-reviewed (e.g. anecdotal and news) reports related to delta-8 THC to summarize current knowledge and implications for public health and...
Addiction (Abingdon, England)
2022
Thomas Knuijver, Arnt Schellekens, Maarten Belgers et al.
49 citations
Ibogaine is an indole alkaloid used in rituals of the African Bwiti tribe. It is also used in non-medical settings to treat addiction. However, ibogaine has been linked to several deaths, mainly due to cardiac events called torsades des pointes preceded by QTc prolongation as well as other safety concerns. This study aimed to evaluate the cardiac, cerebellar and psychomimetic safety of ibogaine...
Addiction (Abingdon, England)
September 1, 2017
Ian Hamilton
The relationship between cannabis and psychosis and schizophrenia has tested the field of addiction for decades, and in some ways serves as measure of our ability to provide a credible contribution to public health. As cannabis is used widely, many people are interested in the risks the drug poses to mental health. This paper focuses upon a seminal study examining this, the trajectory of...
Addiction (Abingdon, England)
April 1, 2017
Daan van der Gouwe, Tibor M Brunt, Margriet Van Laar et al.
72 citations
On-line drug markets flourish and consumers have high expectations of on-line quality and drug value. The aim of this study was to (i) describe on-line drug purchases and (ii) compare on-line with off-line purchased drugs regarding purity, adulteration and price. Comparison of laboratory analyses of 32 663 drug consumer samples (stimulants and hallucinogens) purchased between January 2013 and...
Addiction (Abingdon, England)
October 2010
Judson A Brewer, Sarah Bowen, Joseph T Smith et al.
Both depression and substance use disorders represent major global public health concerns and are often co-occurring. Although there are ongoing discoveries regarding the pathophysiology and treatment of each condition, common mechanisms and effective treatments for co-occurring depression and substance abuse remain elusive. Mindfulness training has been shown recently to benefit both...
Addiction (Abingdon, England)
January 2010
Celia J A Morgan, Leslie Muetzelfeldt, H Valerie Curran
'Recreational' use of ketamine is spreading rapidly among young people. In healthy individuals an acute dose of the N-methyl D-aspartate (NMDA) receptor antagonist ketamine induces marked psychosis-like effects and cognitive impairments, but little is known about the long-term effects of the drug. To evaluate the long-term neuropsychiatric or cognitive consequences. A total of 150 individuals...
Addiction (Abingdon, England)
May 1, 2007
Sundeep Singh
52 citations
Salvia divinorum is a non-water-soluble hallucinogen that is becoming increasingly popular among adolescents. Salvia is a highly selective full agonist of primate and cloned human cerebral kappa-opioid receptors, although its psychotomimetic effects are similar to serotonergic agonists and NMDA glutamate antagonists. Salvia has been associated with depersonalization, laughter, feelings of...
Addiction (Abingdon, England)
December 1, 2001
Diana J Walker, James P Zacny
To determine effects of ethanol-use history and ethanol pretreatment on abuse liability of nitrous oxide (N(2)O). Placebo-controlled, double-blind, cross-over design evaluating effects of N(2)O, 0% (100% O(2), placebo) and 30% (in O(2)), in the presence of three doses of ethanol: 0 g/kg (placebo), 0.35 g/kg and 0.7 g/kg. Subjects sat in a reclining chair in a hospital laboratory. Eight healthy...
Addiction (Abingdon, England)
December 1, 1999
James P Zacny, D Janiszewski, P Sadeghi et al.
To characterize the reinforcing, subjective and psychomotor effects of sevoflurane, a volatile anesthetic, across a range of subanesthetic concentrations in non-drug-abusing humans. In addition, a concentration of nitrous oxide was included in the design in order to compare and contrast behavioral effects of a gaseous to a volatile anesthesic. Repeated measures, double-blind, placebo control...
Addiction (Abingdon, England)
August 1, 1994
A N Chowdhury, N K Bera
Koro in the background of drug abuse is quite rare. The present report of Koro during the first experience with cannabis is the only account of its kind in the world Koro literature to date. The nature and extent of this genital depersonalization is discussed.